Combination Chemotherapy in Treating Patients With Bladder Cancer
Genitourinary Cancer
-
-
Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer
-
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
-
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
-
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
-
Sharing News from the Alliance: September Media Mentions
The media relations efforts from Alliance staff and researchers are designed to alert the public about the vital work happening across our network. When we share stories about clinical trial results, scientific milestones, or investigator achievements, we are showcasing the real-world progress you help make possible. See where the Alliance was mentioned September 2026 in…
-
Alliance Webinar Showcases Latest Cancer Research from 2026 ASCO Meeting
Public October 1 event will feature key treatment advances impacting people with breast, lung and prostate cancers New research is changing what we know about breast, lung, and prostate cancers. On Thursday, October 1, the Alliance for Clinical Trials in Oncology will host a public webinar highlighting key findings from Alliance and Alliance Foundation Trials…
-
Sharing News from the Alliance: August Media Mentions
Our media relations efforts are designed to inform the public about the vital work taking place across our clinical trials network. By sharing stories about clinical trial results, scientific milestones, and investigator achievements, we highlight the real-world progress made possible through the collective efforts of researchers, trial participants, and the broader cancer community. More than…
-
Alliance Reports Results from First Randomized Trial of a Radiopharmaceutical in Kidney Cancer
RadiCaL study results show adding bone-targeting radium-223 to cabozantinib does not improve symptomatic skeletal-related events, highlighting the value of current standard treatments to optimize bone health for patients with bone metastases. Results from the Alliance for Clinical Trials in Oncology’s Phase II RadiCaL trial (Alliance A031801), the first randomized study of a radiopharmaceutical in kidney…